Celularity Inc (CELU)vsVertex Pharmaceuticals Inc (VRTX)
CELU
Celularity Inc
$1.21
-4.72%
HEALTHCARE · Cap: $35.18M
VRTX
Vertex Pharmaceuticals Inc
$454.97
-0.27%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 29476% more annual revenue ($12.00B vs $40.58M). VRTX leads profitability with a 32.9% profit margin vs -2.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
CELU
Avoid19
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CELU.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -63.7% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CELU profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.79 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 19/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a leading biotechnology firm focused on transforming the landscape of regenerative medicine through its unique therapeutic cellular products derived from the placenta. With a strong pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, the company aims to enhance treatment efficacy while reducing associated complications for cancer and other serious illnesses. Driven by an experienced leadership team and strategic partnerships, Celularity is well-positioned to address significant unmet medical needs, solidifying its role as a key player in the rapidly evolving field of advanced therapeutics.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?